JNJ | Weekly | Haru Insights

The Illinois Appellate Court’s unanimous affirmation of a $45 million talc-related verdict against Johnson & Johnson marks a watershed moment, upholding liability and effectively nullifying JNJ’s corporate restructuring defense strategy, setting a dangerous precedent for future litigation.
FDA approval of icotrokinra (Icotyde), the first oral targeted peptide therapy for plaque psoriasis, cements JNJ’s leadership in next-generation immunology and unlocks a high-growth, differentiated therapeutic category with minimal competitive overlap.

Icotyde’s FDA approval positions JNJ as a first-mover in oral targeted peptide therapy, creating a de facto monopoly in a novel treatment class and offering explosive revenue potential across autoimmune and inflammatory diseases with limited near-term competition.
JNJ’s dual-energy THERMOCOOL SMARTTOUCH SF Platform is a breakthrough in cardiac ablation, showcasing unmatched innovation in medtech and solidifying its dominance in cardiovascular interventions with clear clinical and commercial differentiation.
The 64-year dividend growth streak, backed by a conservative 48% payout ratio and $22.1 billion in cash, demonstrates extraordinary financial prudence and makes JNJ a rare haven for income investors seeking reliable, compoundable yield.
Ken Griffin’s 146% stake increase signals elite institutional confidence in JNJ’s long-term resilience and defensive moat, confirming that even in a tech-dominated marketscape, JNJ remains a cornerstone of capital preservation and growth.
With strong earnings beats and consistent revenue growth, JNJ continues to deliver on operational excellence, proving its ability to maintain profitability and shareholder returns amid systemic macro and legal headwinds.

Johnson & Johnson (JNJ)[Tv]